A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2017-06-20 / Oncotarget 2017 Jun;8(25):41538-41548Immunotherapy for the treatment of multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2017-01-27 / Crit. Rev. Oncol. Hematol. 2017 Mar;111:87-93Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2017-01-06 / Pharmacotherapy 2017 01;37(1):129-143Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Multiple Myeloma /von 2017-01-01 / Curr Cancer Drug Targets 2017;17(9):782-805Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2016-11-23 / Exp. Hematol. 2017 Feb;46:48-55Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2016-11-14 / Bone Marrow Transplant. 2017 Feb;52(2):228-237Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2015-10-01 / J. Immunother. 2015 Oct;38(8):330-9Vaccination of multiple myeloma: Current strategies and future prospects
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2015-06-18 / Crit. Rev. Oncol. Hematol. 2015 Nov;96(2):339-54Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2015-04-14 / Chonnam Med J 2015 Apr;51(1):1-7IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de